751 related articles for article (PubMed ID: 21787319)
21. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
McClean PL; Gault VA; Harriott P; Hölscher C
Eur J Pharmacol; 2010 Mar; 630(1-3):158-62. PubMed ID: 20035739
[TBL] [Abstract][Full Text] [Related]
22. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Ho L; Qin W; Pompl PN; Xiang Z; Wang J; Zhao Z; Peng Y; Cambareri G; Rocher A; Mobbs CV; Hof PR; Pasinetti GM
FASEB J; 2004 May; 18(7):902-4. PubMed ID: 15033922
[TBL] [Abstract][Full Text] [Related]
23. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.
Gault VA; Hölscher C
Eur J Pharmacol; 2008 Jun; 587(1-3):112-7. PubMed ID: 18466898
[TBL] [Abstract][Full Text] [Related]
24. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
Bassil F; Fernagut PO; Bezard E; Meissner WG
Prog Neurobiol; 2014 Jul; 118():1-18. PubMed ID: 24582776
[TBL] [Abstract][Full Text] [Related]
25. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
26. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
Jiao JJ; Hölscher C; Li T; Dong XF; Qu XS; Cao Y; Wu MN; Wang ZJ; Qi JS
Sheng Li Xue Bao; 2017 Apr; 69(2):135-145. PubMed ID: 28435972
[TBL] [Abstract][Full Text] [Related]
27. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.
Bomba M; Granzotto A; Castelli V; Onofrj M; Lattanzio R; Cimini A; Sensi SL
J Alzheimers Dis; 2019; 70(3):793-810. PubMed ID: 31256135
[TBL] [Abstract][Full Text] [Related]
28. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.
Wang ZJ; Han YF; Zhao F; Yang GZ; Yuan L; Cai HY; Yang JT; Holscher C; Qi JS; Wu MN
Horm Behav; 2020 Feb; 118():104640. PubMed ID: 31765661
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
[TBL] [Abstract][Full Text] [Related]
30. Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection.
Caraci F; Spampinato S; Sortino MA; Bosco P; Battaglia G; Bruno V; Drago F; Nicoletti F; Copani A
Cell Tissue Res; 2012 Jan; 347(1):291-301. PubMed ID: 21879289
[TBL] [Abstract][Full Text] [Related]
31. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
Shi L; Zhang Z; Li L; Hölscher C
Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971
[TBL] [Abstract][Full Text] [Related]
32. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
Sharma MK; Jalewa J; Hölscher C
J Neurochem; 2014 Feb; 128(3):459-71. PubMed ID: 24112036
[TBL] [Abstract][Full Text] [Related]
34. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
Cao Y; Hölscher C; Hu MM; Wang T; Zhao F; Bai Y; Zhang J; Wu MN; Qi JS
Eur J Pharmacol; 2018 May; 827():215-226. PubMed ID: 29551659
[TBL] [Abstract][Full Text] [Related]
35. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
Hölscher C
Br J Pharmacol; 2022 Feb; 179(4):695-714. PubMed ID: 33900631
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
Ji C; Xue GF; Li G; Li D; Hölscher C
Rev Neurosci; 2016 Jan; 27(1):61-70. PubMed ID: 26351802
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effects of geniposide on Alzheimer's disease pathology.
Liu W; Li G; Hölscher C; Li L
Rev Neurosci; 2015; 26(4):371-83. PubMed ID: 25879319
[TBL] [Abstract][Full Text] [Related]
38. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
Calsolaro V; Edison P
CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
[TBL] [Abstract][Full Text] [Related]
39. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
Zhang ZQ; Hölscher C
Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
[TBL] [Abstract][Full Text] [Related]
40. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
